Identification of somatic mutations in some cancers is useful for targeting therapies, for example, epithelial growth factor receptor (EGFR) mutations for non‐small cell lung carcinoma (Paez et al., 2004; Gazdar, 2009); proto‐oncogene tyrosine‐protein kinase (KIT) mutations for chronic myeloid leukemia, gastrointestinal stromal tumors and melanoma (Heinrich, Blanke, Druker, & Corless, 2002; Willmore‐Payne, Holden, Tripp, & Layfield, 2005); or B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) for melanoma and papillary thyroid cancer (Davies et al., 2002; Kimura et al., 2003). This evidence concerns the gene MARK2 and melanoma.